Clinicopathological role of kidney injury molecule-1 in immunoglobulin A nephropathy

´ëÇѽÅÀåÇÐȸÁö 2014³â 33±Ç 3È£ p.139 ~ p.143

ÀÌÀ¯È£(Lee Yu-Ho) - Kyung Hee University School of Medicine Department of Internal Medicine
±è¾ç±Õ(Kim Yang-Gyun) - Kyung Hee University School of Medicine Department of Internal Medicine
ÀÌ»óÈ£(Lee Sang-Ho) - Kyung Hee University School of Medicine Department of Internal Medicine
¹®ÁÖ¿µ(Moon Ju-Young) - Kyung Hee University School of Medicine Department of Internal Medicine
Á¤°æÈ¯(Jeong Kyung-Hwan) - Kyung Hee University School of Medicine Department of Internal Medicine
ÀÌÅ¿ø(Lee Tae-Won) - Kyung Hee University School of Medicine Department of Internal Medicine
ÀÓõ±Ô(Ihm Chun-Gyoo) - Kyung Hee University School of Medicine Department of Internal Medicine

Abstract

Background: Urinary kidney injury molecule-1 (KIM-1) is an early and sensitive biomarker of acute kidney injury, but it is unclear if it is a biomarker of chronic glomerulonephritis. We evaluated whether urinary KIM-1 levels in patients with immunoglobulin A (IgA) nephropathy can be a marker to re?ect clinicopathological severity and predict the prognosis.

Methods: We measured urinary KIM-1 levels in 40 patients (15 males; mean age 36.6712.9 years) with IgA nephropathy and 10 healthy people (5 males; mean age 37.379.6 years) as controls. The correlation of urinary KIM-1 levels with patients¡¯ clinical parameters, histological grades, and follow-up data were analyzed using the modi?ed H. S. Lee grading system and tubulointerstitial change scores.

Results: Urinary KIM-1 levels were higher in patients with IgA nephropathy than healthy controls (P¨ù0.001). Univariate and multivariate regression analyses showed that urinary KIM-1 levels had a direct correlation with H. S. Lee grade and tubulointerstitial in?ammation (P¨ù0.004 and P¨ù0.011, respectively).

Conclusion: In patients with IgA nephropathy, urinary KIM-1 has a signi?cant correlation with histopathologic severity.

Ű¿öµå

IgA nephropathy, Kidney biomarkers, Kidney injury molecule-1 (KIM-1)
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå